Literature DB >> 24096946

Mediastinoscopy: trends and practice patterns in the United States.

Krishna S Vyas1, Daniel L Davenport, Victor A Ferraris, Sibu P Saha.   

Abstract

OBJECTIVES: Historically, mediastinoscopy has been the gold standard for the staging of lung cancer. A practice gap exists as the result of a variation in knowledge concerning current trends and practice patterns of mediastinoscopy usage. In addition, there are regional variations in practice-based learning and patient care. Lessons learned during surgeries performed on patients with lung cancer and other advances such as positron emission tomography and endobronchial ultrasound could be universally applied to improve surgeons' management of patient care. The purpose of this study was to assess contemporary practices in the staging of lung cancer.
METHODS: We queried the Society of Thoracic Surgeons National Database for data regarding mediastinoscopy usage, yield, and variation, both by year and region.
RESULTS: Cases with mediastinoscopy, as a percentage of all cases performed in the database, have significantly decreased from 14.6% in 2006 to 11.4% in 2010 (P < 0.001). The 5-year median rate of mediastinoscopy in lung cancer patients at 163 centers was 15.3% (interquartile range 5.2%-31.7%), indicating significant variation among centers. The overall median center rate also decreased over time from 21.4% (2006) to 10.0% (2010).
CONCLUSIONS: With advances in minimally invasive procedures and imaging, mediastinoscopy usage has declined significantly. Our findings are likely to be relevant to both clinical practice and practice guidelines.

Entities:  

Mesh:

Year:  2013        PMID: 24096946      PMCID: PMC4387790          DOI: 10.1097/SMJ.0000000000000000

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  37 in total

1.  Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.

Authors:  M A Farrell; H P McAdams; J E Herndon; E F Patz
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

2.  Complication rates in mediastinoscopy and training: video versus conventional mediastinoscopy.

Authors:  Mustafa Zakkar; Ian Hunt
Journal:  Ann Thorac Surg       Date:  2012-07       Impact factor: 4.330

3.  Mediastinoscopy: still the gold standard.

Authors:  Joseph B Shrager
Journal:  Ann Thorac Surg       Date:  2010-06       Impact factor: 4.330

Review 4.  Is video mediastinoscopy a safer and more effective procedure than conventional mediastinoscopy?

Authors:  Mustafa Zakkar; Carol Tan; Ian Hunt
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-17

5.  Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate.

Authors:  Anthony Lemaire; Ivana Nikolic; Thomas Petersen; Jack C Haney; Eric M Toloza; David H Harpole; Thomas A D'Amico; William R Burfeind
Journal:  Ann Thorac Surg       Date:  2006-10       Impact factor: 4.330

6.  A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer.

Authors:  Gonzalo V Gonzalez-Stawinski; Anthony Lemaire; Faisal Merchant; Elizabeth O'Halloran; R Edward Coleman; David H Harpole; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

7.  Preoperative staging of lung cancer with combined PET-CT.

Authors:  Barbara Fischer; Ulrik Lassen; Jann Mortensen; Søren Larsen; Annika Loft; Anne Bertelsen; Jesper Ravn; Paul Clementsen; Asbjørn Høgholm; Klaus Larsen; Torben Rasmussen; Susanne Keiding; Asger Dirksen; Oke Gerke; Birgit Skov; Ida Steffensen; Hanne Hansen; Peter Vilmann; Grete Jacobsen; Vibeke Backer; Niels Maltbaek; Jesper Pedersen; Henrik Madsen; Henrik Nielsen; Liselotte Højgaard
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

Review 8.  The complete ''medical'' mediastinoscopy (EUS-FNA + EBUS-TBNA).

Authors:  P Vilmann; R Puri
Journal:  Minerva Med       Date:  2007-08       Impact factor: 4.806

9.  Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung.

Authors:  W P Luke; F G Pearson; T R Todd; G A Patterson; J D Cooper
Journal:  J Thorac Cardiovasc Surg       Date:  1986-01       Impact factor: 5.209

Review 10.  False positive and false negative FDG-PET scans in various thoracic diseases.

Authors:  Jung Min Chang; Hyun Ju Lee; Jin Mo Goo; Ho-Young Lee; Jong Jin Lee; June-Key Chung; Jung-Gi Im
Journal:  Korean J Radiol       Date:  2006 Jan-Mar       Impact factor: 3.500

View more
  6 in total

Review 1.  Interventional Pulmonology: A Brave New World.

Authors:  Hardeep S Kalsi; Ricky Thakrar; Andre F Gosling; Shahzad Shaefi; Neal Navani
Journal:  Thorac Surg Clin       Date:  2020-08       Impact factor: 1.750

2.  Computer Modeling to Evaluate the Impact of Technology Changes on Resident Procedural Volume.

Authors:  Tyler R Grenda; Tiffany N S Ballard; Andrea T Obi; William Pozehl; F Jacob Seagull; Ryan Chen; Amy M Cohn; Mark S Daskin; Rishindra M Reddy
Journal:  J Grad Med Educ       Date:  2016-12

3.  Costs of Biopsy and Complications in Patients with Lung Cancer.

Authors:  Yu-Wen Chiu; Yu-Hsiang Kao; Michael J Simoff; David E Ost; Oliver Wagner; James Lavin; Richard A Culbertson; Dean G Smith
Journal:  Clinicoecon Outcomes Res       Date:  2021-03-17

4.  Biopsy frequency and complications among lung cancer patients in the United States.

Authors:  Yichen Zhang; Lizheng Shi; Michael J Simoff; Oliver J Wagner; James Lavin
Journal:  Lung Cancer Manag       Date:  2020-08-17

5.  Understanding the patient journey to diagnosis of lung cancer.

Authors:  Yichen Zhang; Michael J Simoff; David Ost; Oliver J Wagner; James Lavin; Beth Nauman; Mei-Chin Hsieh; Xiao-Cheng Wu; Brian Pettiford; Lizheng Shi
Journal:  BMC Cancer       Date:  2021-04-14       Impact factor: 4.430

Review 6.  Convex probe endobronchial ultrasound: historical, contemporary, and cutting-edge applications.

Authors:  Sameer K Avasarala; Carlos Aravena; Francisco A Almeida
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.